A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
Status: | Completed |
---|---|
Conditions: | Migraine Headaches |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 5/27/2013 |
Start Date: | November 2012 |
End Date: | March 2013 |
Contact: | Allergan Inc. |
Email: | clinicaltrials@allergan.com |
This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in
patients with Chronic Migraine.
Inclusion Criteria:
- History of chronic migraines
- 15 or more headache days over a 30 day period
- A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a
minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between
155 and 195 units
Exclusion Criteria:
- Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
We found this trial at
1
site
Click here to add this to my saved trials
